Evidence map›Paper›PMID 38312605›Full record

ArticleHeliyon2024

A mixture of

Jisun Song, Suhyun Han, Sooyeon Choi, Jungkyu Lee, Yoonseon Jeong, Hyun Myung Lee, JongDai Son, Dam Yeon Jeong, Seung-Shin Yu, Wonwoo Lee

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jisun SongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Suhyun HanR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Sooyeon ChoiR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Jungkyu LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Yoonseon JeongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Hyun Myung LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
JongDai SonR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Dam Yeon JeongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Seung-Shin YuR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Wonwoo LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul 07794, South Korea.
Helixmith (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is caused by increased bone resorption due to the excessive activity of osteoclasts.

Indexed as

Herbal extractsOsteoclastOsteoporosisPlatycodon grandiflorumPueraria lobata

Identifiers

PMID38312605
PMCPMC10835310
OpenAlexW4391244215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.